19.02USD-0.24%Mkt Cap: 1.40B USDP/E: —Last update: 2026-06-01
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Na…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.40B USD
Enterprise Value1.06B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-227.32M USD
Revenue/Share—
Last Price19.02 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees130
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.57
PEG—
EV/EBITDA-4.37
EV/Revenue—
P/S—
P/B5.45
EPS (TTM)-3.88
EPS (Forward)-3.45
52W Range
5.95023% of range62.75
52W High62.75 USD
52W Low5.950 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-74.66%
ROA-53.56%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-196.01M USD
CapEx (TTM)35.00K USD
FCF Margin—
FCF Yield-8.61%
Net Debt-318.26M USD
Net Debt/EBITDA1.31
Balance Sheet
Debt/Equity0.25
Current Ratio9.27
Quick Ratio8.77
Book Value/Sh3.522 USD
Cash/Share5.493 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Target (Mean)27.62 USD
Target Range6.000 USD – 46.00 USD
# Analysts13
Ownership
Shares Out.73.62M
Float38.25M
Insiders9.68%
Institutions87.72%
Short Interest
Short Ratio6.0d
Short % Float10.88%
Short % Out.7.43%
Shares Short5.47M
Short (prev mo.)6.65M
Technical
SMA 5017.51 (+8.6%)
SMA 20021.55 (-11.8%)
Beta1.01
S&P 52W Chg27.94%
Avg Vol (30d)822.17K
Avg Vol (10d)747.55K
Technical Indicators
RSI (14)59.6
MACD0.3141
MACD Signal0.1527
MACD Hist.+0.1615
BB Upper19.45 USD
BB Middle17.79 USD
BB Lower16.13 USD
BB Width18.64%
ATR (14)0.9919 USD
Vol Ratio (20d)0.76x